# Sources — Frédéric Chopin

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

Accessed November 4, 2026. The canonical source metadata and claim links are in `case.json`.

## Historical evidence

1. Smoleńska-Zielińska B. “Biography: general outline.” The Fryderyk Chopin Institute (chopin.pl). Supports his birth at Żelazowa Wola on March 1, 1810, by his own and his family's account, with February 22 on the baptismal certificate written several weeks later; his father, a Frenchman from Lorraine who settled in Poland and raised his children as Poles; the family's move to Warsaw; teaching as his main income in Paris and his dislike of public performance; the 1836 engagement accepted on condition that he take better care of his health and ended after a serious winter illness; the Majorca winter of 1838 to 1839, where he became gravely ill and showed symptoms of tuberculosis; the convalescence in Marseille and the move to Nohant still greatly weakened; the effect of the 1847 parting on his mental and physical state; the 1848 tour and his last concert despite frailty and fever; and his death of pulmonary tuberculosis in the Place Vendôme on October 17, 1849, with his heart taken to the Holy Cross Church in Warsaw. https://chopin.pl/biography_chopin.en.html
2. Polish Music Information Centre (POLMIC). “Chopin Fryderyk: a calendar of the composer's life.” Supports March 1 (or, for some historians, February 22) 1810; his departure from Warsaw on November 2, 1830, never to return; Paris from September 1831; his choice in 1834 of political-refugee status; the conditional engagement of 1836; his meeting with George Sand in 1836 and their closer relationship from 1838; the damp Majorca winter that badly affected his health; the last London concert on November 16, 1848; the two hemorrhages on June 22, 1849, after which a physician diagnosed tuberculosis in its final stage; and his death and burial. https://polmic.pl/en/encyclopedia/subject-entries/c/chopin-fryderyk-en
3. Schmid-Adamczyk B. “Fryderyk Chopin and George Sand: the trip to Majorca.” The Fryderyk Chopin Institute (chopin.pl). Supports the dates on Majorca (Palma from November 8, 1838; Son Vent; Valldemossa from December 15, 1838, to February 11, 1839), the cold and damp that worsened his health, the doctors called, his letter of December 3, 1838 (“I became sick as a dog over the last two weeks”), the owner who, prompted by neighbors fearing an infectious disease, forced them out, the hostility of local people who feared his illness, his “long periods of doubt and depression, associated with illness,” and the convalescence in Marseille under a physician until May 1839. https://www.chopin.pl/majorca.en.html
4. Narodowy Instytut Fryderyka Chopina. “Fryderyk Chopin: routes, family.” Supports that his youngest sister, Emilia, died of tuberculosis in 1827. https://greatcomposers.nifc.pl/en/chopin/routes/71_family
5. Witt M, Szklener A, Kawecki J, et al. “A Closer Look at Frederic Chopin's Cause of Death.” *Am J Med.* 2018;131(2):211-212 (published online October 12, 2017). PMID 29031593. https://pubmed.ncbi.nlm.nih.gov/29031593/
6. Witt M, Szklener A, Marchwica W, Dobosz T. “Disease not genetic but infectious: multiple tuberculomas and fibrinous pericarditis as symptoms pathognomonic for tuberculosis of Frederic Chopin.” *J Appl Genet.* 2018;59(4):471-473. The abstract describes the enlarged heart with fibrinous pericarditis and nodular foci (“frosted heart”), presumably tubercular, and concludes that chronic tuberculosis is the most plausible diagnosis and tuberculous pericarditis the immediate cause of death. https://pubmed.ncbi.nlm.nih.gov/30047032/
7. Witt M, Dobosz T. “Inheritance vs. infectivity as a mechanism of malady and death of Frederic Chopin.” *J Appl Genet.* 2021;62(4):607-611. States that the heart was examined macroscopically in 2014 and that long-lasting tuberculosis was, with high probability, the primary disease. https://pubmed.ncbi.nlm.nih.gov/34347238/
8. Majka L, Goździk J, Witt M. “Cystic fibrosis: a probable cause of Frédéric Chopin's suffering and death.” *J Appl Genet.* 2003;44(1):77-84. https://pubmed.ncbi.nlm.nih.gov/12590184/
9. Eriksson S. “Did Chopin suffer of antitrypsin deficiency?” *Läkartidningen.* 2003;100(30-31):2449-54 (in Swedish; title and record only). https://pubmed.ncbi.nlm.nih.gov/12914142/
10. Perciaccante A, Charlier P, Negri C, et al. “Did Frédéric Chopin Die From Heart Failure?” *J Card Fail.* 2018;24(5):342-344. The abstract summarizes his documented symptoms and proposes dilated cardiomyopathy with heart failure and cirrhosis. https://pubmed.ncbi.nlm.nih.gov/29597050/
11. Young P, Bernaciak JM, Bruetman JE, et al. “Frederic Chopin (1810-1849), and his disease.” *Rev Med Chil.* 2014;142(4):529-35. Reviews tuberculosis, cystic fibrosis, and alpha-1 antitrypsin deficiency and judges tuberculosis the most probable. https://pubmed.ncbi.nlm.nih.gov/25117047/
12. HISTMED Master Roster v3. Internal project source. Its clinical claims (tuberculosis, “probable cystic fibrosis variant,” depression, hemoptysis, frailty) were provisional and were not treated as independent corroboration.

## Clinical guidance

1. Carr W, Kurbatova E, Starks A, et al. Interim guidance: 4-month rifapentine-moxifloxacin regimen for the treatment of drug-susceptible pulmonary tuberculosis, United States, 2022. *MMWR* 2022;71(8):285-289 (PMID 35202353). Eligibility (age 12 or older, weight at least 40 kg; not for pregnancy, most extrapulmonary disease, prolonged QT, interacting drugs, or known resistance), doses (rifapentine 1200 mg, moxifloxacin 400 mg, isoniazid 300 mg with pyridoxine, pyrazinamide by weight band), 56 then 63 daily doses with food, observation of at least five of seven weekly doses, the completion windows (56 doses within 70 days, 63 within 84 days, all within five months), baseline tests (liver tests, platelets, creatinine, potassium, calcium, magnesium, HIV, hepatitis B and C), ECG only if indicated, monthly sputum until two cultures are negative, and repeat susceptibility for a positive two-month culture. https://www.cdc.gov/mmwr/volumes/71/wr/mm7108a1.htm
2. American Thoracic Society, CDC, and IDSA. Clinical practice guidelines: treatment of drug-susceptible tuberculosis (2016). https://pubmed.ncbi.nlm.nih.gov/27621353/
3. ATS, CDC, ERS, and IDSA. Updates on the treatment of drug-susceptible and drug-resistant tuberculosis (2025), which adds the four-month regimen for pulmonary tuberculosis. https://pubmed.ncbi.nlm.nih.gov/40693952/
4. American Thoracic Society. An official ATS statement: hepatotoxicity of antituberculosis therapy (2006). https://pubmed.ncbi.nlm.nih.gov/17021358/
5. National Tuberculosis Controllers Association and CDC. Guidelines for the investigation of contacts of persons with infectious tuberculosis (2005). https://pubmed.ncbi.nlm.nih.gov/16357823/
6. Farrell PM, et al. Diagnosis of cystic fibrosis: consensus guidelines from the Cystic Fibrosis Foundation (2017). Sweat chloride below 30 mmol/L makes cystic fibrosis unlikely. https://pubmed.ncbi.nlm.nih.gov/28129811/
7. American Thoracic Society and European Respiratory Society. Standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency (2003). https://pubmed.ncbi.nlm.nih.gov/14522813/
8. Academy of Nutrition and Dietetics and ASPEN. Consensus characteristics for adult malnutrition (2012). https://pubmed.ncbi.nlm.nih.gov/22535923/
9. American College of Physicians and CDC. Appropriate antibiotic use for acute respiratory tract infection in adults (2016) (sick visit). https://pubmed.ncbi.nlm.nih.gov/26785402/
10. U.S. Preventive Services Task Force: depression and suicide risk (2023) and A and B recommendations; CDC adult immunization schedule; Medicare Preventive Services reference (Aether Forge, 2026). https://www.uspreventiveservicestaskforce.org/uspstf/recommendation-topics/uspstf-a-and-b-recommendations, https://www.cdc.gov/vaccines/hcp/imz-schedules/adult-age.html, https://patrickrutledge.github.io/preventative_services/

The CMID (Aether Forge, 2026) has no tuberculosis, malnutrition, or other monograph covering this case's conditions, so it is not cited.

## Editorial resolutions

- **Name.** The display name is Frédéric Chopin. The roster spells it “Frederick Chopin”; the French form he used in Paris is preferred. The aliases are the Polish forms, Fryderyk Chopin and Fryderyk Franciszek Chopin, which appear in no other record. The name splits simply into a given name and a family name, so identity.name_parts is not needed.
- **Birth date.** March 1, 1810, the date he and his family used and the Institute gives, is preferred; February 22, 1810, from the baptismal certificate written several weeks after the birth, is recorded as a conflicting alternative.
- **Index age and dates.** Synthetic date of birth March 1, 1998; shift 188 years. The index visit on March 17, 2026 (age 28) maps to March 17, 1838. The chronic-care visits on March 20, April 7, May 15, and July 21, 2026, the sick visit on June 9, 2026, and the preventive visit on September 15, 2026 map to the same days of 1838, when he lived and taught in Paris; he left for Majorca at the end of October 1838, after the last visit. The episode is set in the year before the Majorca crisis and ends in cure; that is a synthetic outcome of modern treatment and does not contradict the documented course in the true frame.
- **Presenting problem.** The cough with hemoptysis and weight loss is its own problem (PRB-001, R04.2), resolved at the results visit, when pulmonary tuberculosis (PRB-002, A15.0) is recorded. The intake documents show only the suspicion, the samples, and the plan, with no results or regimen.
- **Choice of diagnosis.** Pulmonary tuberculosis was chosen as the one modern diagnosis because it is the diagnosis made in his lifetime (graded **D**: the Majorca symptoms of tuberculosis and the 1849 diagnosis after two hemorrhages), the cause of death the Institute gives, and the conclusion of the 2014 examination of his heart (graded **R**, probable: a fibrinous pericarditis with nodules interpreted as tuberculous, judged the probable immediate cause of death). Cystic fibrosis (proposed in 2003), alpha-1 antitrypsin deficiency (proposed in 2003), and dilated cardiomyopathy with heart failure and cirrhosis (proposed in 2018) are **R** and disputed and stay off the problem list. In the modern frame the genetic alternatives are tested honestly (sweat chloride 18 mmol/L, alpha-1 antitrypsin 142 mg/dL, and no bronchiectasis or emphysema on CT), all synthetic, and found absent. The brief described the heart examination as taking place in 2017; the sources show it was examined in 2014 and the Am J Med letter was published online in October 2017, so 2014 is recorded.
- **Regimen.** He is eligible for the four-month rifapentine-moxifloxacin regimen under the 2022 CDC interim guidance (weight 48.4 kg, at least 40 kg; pulmonary only; HIV negative; no QT history or interacting drugs; normal potassium, magnesium, liver tests, and creatinine), and he chose it because it returns him to full work sooner. Pyrazinamide 1000 mg follows the 40 to under 55 kg band. The 2016 ATS/CDC/IDSA guideline is followed for diagnosis, infection control, and monitoring; the CDC guidance does not call for routine electrocardiograms, and none was done. The 2016 guideline was issued by ATS, CDC, and IDSA (and endorsed by ERS), not by all four; the 2025 update is the ATS/CDC/ERS/IDSA document.
- **Microbiology and qualitative tests.** Smears, the amplification test, molecular resistance tests, cultures, phenotypic susceptibility, the interferon-gamma release assay, HIV, and hepatitis serology are recorded in the note text and monitoring tables, because the canonical schema carries only numeric results. All are synthetic.
- **Real people.** George Sand appears only in documented history claims (CLM-0008, CLM-0012); the fiancée's family appears only in the documented 1836 claim, unnamed. His sister's death of tuberculosis in 1827 appears only in the family history and the historical basis. No relative or companion appears in the visit notes, and no decision, statement, or health fact is attributed to any real person in the modern episode. His contacts (students, friends) are synthetic and unnamed, and none of their results is part of his record.
- **Mental health.** The documented “doubt and depression” on Majorca and the effect of the 1847 parting are marked sensitive and kept in the source's lay words; they are after the index date and not shown in intake documents. The modern PHQ-9 scores (7, 4, 3) are synthetic and mild; no depression diagnosis is made, and no safety assessment is required (no F-code, PHQ-9 below 10). Item 9 is recorded as 0 each time.
- **Stigma.** His fear of being shunned (HC-003) echoes the documented fear of his illness on Majorca; the modern episode answers it with information, a timed return to teaching, and a contact investigation run by the health department.
- **Synthetic content.** All laboratory values, imaging, weights (height 170 cm is synthetic), the dosing history, the household and contacts, the dietitian care, the cold, and the preventive care are synthetic.
- **Focused visits.** The four chronic-care follow-ups (the results visit at three days with the consultation, two and a half weeks, the end of the intensive phase, and the end of treatment) are focused visits with protocol monitoring tables built from the 2022 CDC interim guidance and the ATS/CDC/IDSA guideline (symptoms, weight and pyrazinamide band, adverse effects including tendons and nerves, liver tests, electrolytes, ECG not indicated, sputum smear and culture, amplification test, molecular and phenotypic susceptibility, the two-month culture, IGRA, HIV and hepatitis serology, chest X-ray, observed doses and the completion windows, interactions, isolation, reporting, contact investigation, infectious diseases review), the CF Foundation and ATS/ERS standards (sweat chloride and alpha-1 antitrypsin), the malnutrition consensus, and the PHQ-9. One protocol deviation is recorded instead of an invented result: no monthly clinic review took place in the six weeks between the sick visit and the end of treatment; the nurse reviewed symptoms and side effects on every video call and the end-of-treatment findings were normal, so no harm is evident, and monthly reviews are now booked at the start.
- **Sick and preventive visits.** The sick visit is a cold in week 12, chosen to teach how to tell a viral infection from treatment failure, to avoid antibiotics, and to keep zinc and mineral remedies away from moxifloxacin and QT-prolonging drugs such as azithromycin away from it. The preventive visit is the adult preventive service at 28, with influenza vaccine and the screening done at the diagnosis carried forward; no tuberculosis test is repeated. Advance care planning is a brief discussion with no agent named.
- **Consultation.** The infectious diseases referral and the consultation by Ewa Kowalczyk-Grant, MD (a fictional consultant), on the day of the results visit, are **S**. She confirms the diagnosis, sets out his eligibility for the four-month regimen and the doses, the liver, tendon, and nerve monitoring, the release and return-to-teaching criteria, and the tests for cystic fibrosis and alpha-1 antitrypsin deficiency, and plans message reviews at two months and at the end. The record follows these recommendations, apart from the clinic-review gap recorded as a deviation.
- **Not used.** His later life after 1838, the works composed while ill, and the roster's “depression” and “extreme physical frailty” labels are not used as diagnoses. The letters to Nature and Am J Med that comment on the heart examination were not fetched beyond their bibliographic records and are not cited. Wikipedia and other secondary pages found in searches were not used.
